A class-action lawsuit has been filed against Atara Biotherapeutics Inc. (NASDAQ: ATRA), alleging the company made false statements about its lead cancer drug candidate over a 20-month period.
"The complaint alleges defendants made false and/or misleading statements and/or failed to disclose that certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA," law firm Bronstein, Gewirtz & Grossman said in a statement.
The lawsuit, filed on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, claims the company overstated the regulatory prospects of its drug, tabelecleucel. The Schall Law Firm also announced a similar suit, encouraging investors who suffered a loss to contact them before the May 22, 2026, lead plaintiff deadline.
The allegations suggest that undisclosed manufacturing and clinical trial deficiencies exposed Atara to heightened regulatory risk and jeopardized future revenue from its primary drug candidate. The legal proceedings could result in significant financial penalties for the company and further impact its stock value.
According to the complaints issued by both The Schall Law Firm and Bronstein, Gewirtz & Grossman, Atara failed to disclose significant setbacks. The firms allege that these manufacturing issues not only made FDA approval for the Biologics License Application (BLA) for tabelecleucel unlikely but also subjected Atara to a greater risk of regulatory scrutiny.
The lawsuits state that the company’s public statements about the prospects of tabelecleucel were materially false and misleading throughout the class period. Both firms are representing investors on a contingency fee basis and note that a class has not yet been certified.
The legal action against Atara Biotherapeutics highlights the potential financial and reputational risks associated with drug development and regulatory disclosures. Investors will be watching for the company's official response to the allegations and any developments as the May 22, 2026, lead plaintiff deadline approaches.
This article is for informational purposes only and does not constitute investment advice.
